Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 7/20 | 0.52 |
| ▸ | CCR2 | P41597 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190846 | 0.90 | PTGS2 (0.67) | PTGS2ESR1CCR2L3MBTL1BACE1 | |
| SCHEMBL4887683 | 0.87 | L3MBTL1 (0.61) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL28405047 | 0.85 | CCR2 (0.52) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL6085556 | 0.79 | PTGS2 (0.78) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL6086162 | 0.78 | PTGS2 (0.71) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL5357551 | 0.78 | ESR1 (0.49) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL5359543 | 0.78 | ESR1 (0.49) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL28384928 | 0.78 | CCR2 (0.64) | PTGS2ESR1CCR2L3MBTL1ALDH1A1 | |
| SCHEMBL2823906 | 0.77 | L3MBTL1 (0.57) | PTGS2ESR1CCR2L3MBTL1BACE1 | |
| SCHEMBL16632275 | 0.76 | ALDH1A1 (0.47) | PTGS2L3MBTL1BACE1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206124-B2 | Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | PTGS2 2610/4885ESR1 3124/4885CCR2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.